Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-04-24 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制评价报告' which translates to 'Internal Control Evaluation Report'. It discusses the company's internal control environment, risk assessment, control activities, information and communication, and internal supervision. It includes detailed descriptions of internal control mechanisms, evaluation criteria for control deficiencies, and concludes on the effectiveness of internal controls as of December 31, 2024. The document is a standalone report focused on internal control evaluation rather than a full annual report or audit report. It does not present full financial statements but rather an assessment of internal controls, which aligns with the definition of an Audit Report / Information (AR). The document length is 7,714 characters, sufficient to be a full report rather than a brief announcement. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2024
2025-04-24 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary" for the year 2024. It contains detailed financial data such as total assets, net profit, earnings per share, shareholder structure, and dividend distribution plans. It also includes audit information mentioning a standard unqualified opinion from an accounting firm. The length of the document is over 5,000 characters and it contains substantive financial data and analysis, not just an announcement or a certification. Therefore, this document is the actual Annual Report or a summary of it, fitting the definition of an Annual Report (10-K). FY 2024
2025-04-24 Chinese
大华会计师事务所（特殊普通合伙）关于内蒙古大唐药业股份有限公司控股股东及其他关联方资金占用情况的专项说明
Regulatory Filings
2025-04-24 Chinese
2024年度独立董事述职报告（伊利红）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, and activities during the year 2024. The content includes the director's background, attendance at board meetings, committee work, communication with auditors, protection of investors' rights, and overall evaluation and suggestions. It is not an announcement of a report but the report itself. The document length is 2653 characters, which is relatively short but contains substantive content about the director's work and responsibilities, not just a brief announcement or certification. This type of document fits best under Board/Management Information (MANG) as it relates to management-level reporting on governance and director activities rather than financial results or regulatory filings. It is not an Annual Report (10-K), Audit Report (AR), or any other category. Therefore, the classification is MANG with high confidence.
2025-04-24 Chinese
董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references regulatory guidelines from the China Securities Regulatory Commission and the Beijing Stock Exchange, and assesses the independence criteria of the independent directors. The content is focused on governance and compliance with independence requirements rather than financial results or other report types. It is not an announcement of a meeting, voting results, or a financial report. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-04-24 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is titled as a "舆情管理制度" (Public Opinion Management System) issued by the company's board. It details the company's internal policy and procedures for managing public opinion and media reports, including organizational structure, responsibilities, principles, and accountability. It is a governance-related internal policy document rather than a financial report, earnings release, or announcement of voting results. There is no indication of financial data, audit information, or shareholder meeting materials. The document is a formal governance policy issued by the board, which fits the category of Governance Information (CGR). The document length is 3508 characters, which is sufficient for a detailed policy document. Therefore, the appropriate classification is CGR with high confidence.
2025-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.